Efficacy and Safety of PD-1 Inhibitor Plus Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

被引：0

作者：

Qin, Yan ^{[1
]}

He, Xiaohui ^{[1
]}

Yang, Sheng ^{[1
]}

Liu, Peng ^{[1
]}

Zhou, Shengyu ^{[1
]}

Yang, Jianliang ^{[1
]}

Gui, Lin ^{[1
]}

Zhong, Qiaofeng ^{[1
]}

Zhao, Fengyi ^{[1
]}

Shi, Yuankai ^{[1
]}

Jing, Hongmei ^{[2
]}

Zhang, Shiyue ^{[3
]}

Guo, Ruihan ^{[3
]}

Shi, Yuankai ^{[1
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Beijing Key Lab Clin Study Anticanc Mol Targete, Dept Med Oncol, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China

[2] Peking Univ Third Hosp, Dept Hematol, Beijing, Peoples R China

[3] Shanghai Junshi Biosci, Shanghai, Peoples R China

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-152094

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2485

引用

页数：3